With 2025 coming to an end, we sat down with CEO and founder of Cellomatics Biosciences, Dr Shailendra Singh, to get his thoughts on the previous twelve months and his view of where he thinks Cellomatics will be in 2026.
As we approach the end of another impactful year, I am pleased to reflect on the progress, achievements, and milestones that have shaped our journey. Throughout 2025, we have continued to strengthen our scientific capabilities, expand our global presence, and deliver high-quality, biology-driven research to our clients worldwide.
Despite the challenging biotech landscape, our measured and strategic approach has enabled us to navigate uncertainty with resilience. I am proud to share that Cellomatics has achieved a record-breaking revenue turnover for 2024–2025, a testament to the dedication, expertise and hard work of our entire team.
This year also marked significant advancements in our in vitro models, enhanced engagement with international partners, and continued growth in demand for our specialised services. Together, these developments reinforce our mission to support drug discovery and preclinical research with reliable, high-quality science.
Driving science and innovation
Innovation continues to be at the core of everything we do. Throughout the year, we have continued to strengthen and refine our core expertise across inflammatory diseases, immunology, ophthalmology, and dermatology. Several new developments have strengthened our ability to deliver advanced in vitro solutions to clients.
Advancement of organoid-based platforms
At Cellomatics, we are expanding our organoid and 3D in vitro models to provide more human-relevant platforms for drug discovery. These models allow researchers to study disease mechanisms, test new compounds and assess therapeutic responses in systems that closely mimic human biology.
They go beyond traditional animal and 2D cell culture systems, capturing the structural and functional complexity of human tissues. By generating predictive data earlier in the development process, we help pharmaceutical and biotechnology partners make smarter, more informed decisions, reduce late-stage failures, and save time and resources.
We are also extending organoid and complex 3D systems into oncology, immunology and respiratory diseases. Customised co-culture models incorporating epithelial, immune and stromal cells enable more physiologically accurate assessments of drug efficacy, immune modulation, and toxicity.
Beyond scientific advancement, organoid technologies support ethical research by reducing reliance on animal models. These human-relevant systems provide both more reliable data and greater efficiency, accelerating innovation while maintaining high scientific standards.
By integrating organoid technology into preclinical testing, Cellomatics helps its partners advance research in a way that is innovative, ethical and economically sustainable.
Advancements in Ophthalmology and Skin Disease Models
We are making significant progress in developing advanced models for ophthalmology and skin-related research at Cellomatics. Using induced pluripotent stem cell (iPSC) technology, we are creating physiologically relevant eye disease models that allow researchers to study complex cellular interactions, disease mechanisms and therapeutic responses in a human-relevant system. These iPSC-derived models offer the ability to capture patient-specific biology, providing insights that traditional models cannot fully replicate.
In parallel, we are developing skin-based disease models that replicate conditions such as atopic dermatitis, psoriasis, Hidradenitis Suppurativa (HS), scleroderma, cutaneous lupus erythematosus and other dermatological disorders. These models enable detailed investigation of disease progression, inflammation, and treatment responses in a controlled, biologically-relevant environment.
Additionally, our skin models are being adapted for safe and effective cosmetic testing, providing an ethical alternative to animal studies. By combining high-quality human cells with advanced 3D culture techniques, we deliver predictive, reliable data that supports both therapeutic and cosmetic research applications.
Through these advancements, Cellomatics supports clients to explore novel treatments, accelerate development timelines, and achieve more accurate, human-relevant insights, while upholding ethical standards in research.
Enhanced immune cell functional assays
Our team has further refined assays focused on functional immunomodulation, internalisation, and antibody–antigen interactions using primary human cells. These platforms continue to support clients developing next-generation biologics, ADCs, and immunotherapies.
Broader project diversity
This year, we carried out a wide range of complex studies, including epithelial–immune co-culture systems, multi-donor experiments, and translational assays designed around client-specific mechanisms. Each project highlights our commitment to well-planned science and producing high-quality, reliable data.
Business highlights: expanding our global reach
Our commercial expansion has continued to accelerate across both the US and Europe. With dedicated business development presence led by Dr Jyoti Mundra (US) and Dr Pier Amendola (EU), Cellomatics is now better positioned than ever to support clients across time zones, geographies and therapeutic areas.
Key developments include:
- Strengthening our footprint in major biotech hubs across the US West Coast, East Coast and Central Europe.
- Increased face-to-face and virtual engagement with our clients.
- A growing client base reflecting both returning partners and new collaborations established this year.
These strategic investments are enabling meaningful long-term partnerships and expanding access to our specialist in vitro expertise worldwide.
Recognition and achievements
This year brought several proud moments for the Cellomatics team:
Awards finalists and winners
We were honoured to be named Bioscience Innovator of the Year at the Go Global Awards 2025. Cellomatics was also shortlisted for the Pharma Industry Awards 2025—recognition of our scientific excellence, customer service, and company growth.
ISO Accreditation
Achieving ISO certification marks an important organisational milestone. It reflects our commitment to quality, structured processes and continuous improvement—principles that guide every project we deliver.
Together, these achievements highlight both the strength of our scientific capabilities and the dedication of our entire team.
Looking ahead: a perspective for the future
As the biotech and pharma landscape continues to evolve, the need for robust, human-relevant in vitro science becomes even greater. Looking ahead, we see several key opportunities:
- Expansion of organoid platforms using patient-derived materials, enabling more accurate and physiologically relevant disease models.
- Growing demand for primary cell–based assays that better predict clinical responses and support more informed decision-making.
- Stronger collaborations with clients at earlier stages, helping to enhance translational relevance from discovery through candidate selection.
- Strategic growth of our scientific capabilities, ensuring Cellomatics remains at the forefront of innovation in complex in vitro biology.
2025 has been a year of meaningful progress—scientifically, operationally and globally. Our achievements reflect not only the dedication and expertise of our team but also the trust and collaboration of our clients and partners.
As we look ahead, Cellomatics Biosciences remains fully committed to advancing innovative, human-relevant in vitro science that accelerates drug discovery and helps improve patient outcomes worldwide. We will continue to invest in talent, technology, and strategic partnerships, allowing us to maintain the highest scientific standards while delivering the personalised, agile service that our clients value. Through these efforts, we aim to drive meaningful advances in preclinical research and support our partners in bringing safe and effective therapies to patients faster.
I would like to take this opportunity to sincerely thank all our clients for their trust and support over the past year. We look forward to strengthening existing relationships and building new partnerships in 2026, as we continue to deliver high-quality, reliable, and ethically responsible scientific solutions.
